What does in process research and development mean?

This represents the capitalized value of research and development projects acquired through business combinations that have not yet reached technological feasibility. It reflects the investment in future product pipelines and intellectual property that are currently in the clinical or development stage. For biotech firms, this is a primary indicator of the long-term value of the company's therapeutic portfolio.

TuHURA Biosciences, Inc. HURA In Process Research And Development

In Process Research And Development at other companies

SavaraSVRA

$11.36M+5.9%

CTO

Citius Oncology, Inc.CTOR

$71.11M-3.1%

RFL

Rafael Holdings, Inc.RFL

$31.58M0.0%

CTO

Citius Oncology, Inc.CTOR

$18.35M—

NuScale PowerSMR

$16.9M0.0%

Aclaris TherapeuticsACRS

$21.73M+1,211%

Other financials

Income statement

See full

Revenue-—

Net income-$7.5M-13.1%

EPS (diluted)-$0.13+13.3%

Balance sheet

See full

Cash & equivalents$6.3M+1.3%

Total debt$456.9K+178%

Total equity$23.2M+135%

Total assets$29.7M+103%

Cash flow

See full

Operating cash flow-$4.4M+6.9%

CapEx$48.8K+14.5%

Free cash flow-$4.5M+6.7%

Valuation

See full

Market cap$155.39M+45.8%

Enterprise value$149.54M+52.3%

Returns & leverage

See full

Return on equity-187.2%—

Debt / equity0×0.0×

Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept hura:InProcessResearchAndDevelopment.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s in process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s in process research and development?: TuHURA Biosciences, Inc. (HURA) reported in process research and development of $11.28M in Q1 2026.
What does in process research and development mean?: This represents the capitalized value of research and development projects acquired through business combinations that have not yet reached technological feasibility. It reflects the investment in future product pipelines and intellectual property that are currently in the clinical or development stage. For biotech firms, this is a primary indicator of the long-term value of the company's therapeutic portfolio.